TMPRSS2 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
type II pneumocyte	11 studies	31% ± 11%	Explore
type I pneumocyte	10 studies	34% ± 7%	Explore
epithelial cell	7 studies	34% ± 11%	Explore
ciliated cell	6 studies	21% ± 5%	Explore
renal alpha-intercalated cell	6 studies	41% ± 8%	Explore
enterocyte	5 studies	21% ± 4%	Explore
club cell	5 studies	33% ± 7%	Explore
ionocyte	4 studies	20% ± 3%	Explore
squamous epithelial cell	4 studies	58% ± 13%	Explore
luminal cell of prostate epithelium	4 studies	56% ± 3%	Explore
kidney distal convoluted tubule epithelial cell	4 studies	34% ± 5%	Explore
secretory cell	3 studies	26% ± 4%	Explore
brush cell	3 studies	25% ± 7%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
lung	4 studies	17% ± 3%	Explore
intestine	3 studies	17% ± 1%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
prostate	95%	30699.28	233 / 245	100%	809.32	500 / 502
pancreas	100%	9658.46	328 / 328	88%	45.11	157 / 178
stomach	78%	15944.60	280 / 359	94%	82.07	270 / 286
lung	96%	6096.70	556 / 578	63%	37.81	733 / 1155
liver	97%	2672.59	219 / 226	55%	15.04	222 / 406
intestine	51%	9152.62	490 / 966	95%	90.50	499 / 527
thymus	91%	3205.00	596 / 653	36%	10.40	217 / 605
kidney	100%	6259.26	89 / 89	12%	11.53	108 / 901
bladder	33%	1307.33	7 / 21	70%	55.37	354 / 504
ureter	0%	0	0 / 0	100%	129.97	1 / 1
esophagus	36%	1750.26	526 / 1445	51%	40.16	93 / 183
breast	53%	1651.48	243 / 459	29%	7.00	323 / 1118
tonsil	0%	0	0 / 0	51%	24.93	23 / 45
skin	40%	655.34	731 / 1809	1%	0.25	6 / 472
uterus	4%	47.26	6 / 170	36%	15.67	164 / 459
ovary	1%	10.32	1 / 180	2%	0.36	8 / 430
adipose	1%	24.62	15 / 1204	0%	0	0 / 0
adrenal gland	0%	0	0 / 258	0%	0.07	1 / 230
brain	0%	0	0 / 2642	0%	0.22	3 / 705
blood vessel	0%	7.74	3 / 1335	0%	0	0 / 0
peripheral blood	0%	2.47	1 / 929	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
eye	0%	0	0 / 0	0%	0	0 / 80
gingiva	0%	0	0 / 0	0%	0	0 / 0
heart	0%	0	0 / 861	0%	0	0 / 0
lymph node	0%	0	0 / 0	0%	0	0 / 29
muscle	0%	0	0 / 803	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
spleen	0%	0	0 / 241	0%	0	0 / 0

III. Associated gene sets

GO_0016540	Biological process	protein autoprocessing
GO_0019081	Biological process	viral translation
GO_0046598	Biological process	positive regulation of viral entry into host cell
GO_0006508	Biological process	proteolysis
GO_0070062	Cellular component	extracellular exosome
GO_0005654	Cellular component	nucleoplasm
GO_0005576	Cellular component	extracellular region
GO_0005886	Cellular component	plasma membrane
GO_0008236	Molecular function	serine-type peptidase activity
GO_0005515	Molecular function	protein binding
GO_0004252	Molecular function	serine-type endopeptidase activity

IV. Literature review

[source]

Gene name	TMPRSS2
Protein name	Transmembrane serine protease 2 Epitheliasin Transmembrane protease serine 2 (EC 3.4.21.122) (Serine protease 10) [Cleaved into: Transmembrane protease serine 2 non-catalytic chain; Transmembrane protease serine 2 catalytic chain] Transmembrane protease serine 2
Synonyms	PRSS10
Description	FUNCTION: Plasma membrane-anchored serine protease that cleaves at arginine residues . Participates in proteolytic cascades of relevance for the normal physiologic function of the prostate . Androgen-induced TMPRSS2 activates several substrates that include pro-hepatocyte growth factor/HGF, the protease activated receptor-2/F2RL1 or matriptase/ST14 leading to extracellular matrix disruption and metastasis of prostate cancer cells . In addition, activates trigeminal neurons and contribute to both spontaneous pain and mechanical allodynia (By similarity). .; FUNCTION: (Microbial infection) Facilitates human coronaviruses SARS-CoV and SARS-CoV-2 infections via two independent mechanisms, proteolytic cleavage of ACE2 receptor which promotes viral uptake, and cleavage of coronavirus spike glycoproteins which activates the glycoprotein for host cell entry . The cleavage of SARS-COV2 spike glycoprotein occurs between the S2 and S2' site . Upon SARS-CoV-2 infection, increases syncytia formation by accelerating the fusion process . Proteolytically cleaves and activates the spike glycoproteins of human coronavirus 229E (HCoV-229E) and human coronavirus EMC (HCoV-EMC) and the fusion glycoproteins F0 of Sendai virus (SeV), human metapneumovirus (HMPV), human parainfluenza 1, 2, 3, 4a and 4b viruses (HPIV). Essential for spread and pathogenesis of influenza A virus (strains H1N1, H3N2 and H7N9); involved in proteolytic cleavage and activation of hemagglutinin (HA) protein which is essential for viral infectivity. .
Accessions	C9J5Y1 ENST00000424093.6 ENST00000677680.1 ENST00000678743.1 ENST00000332149.10 [O15393-1] O15393 ENST00000454499.6 [O15393-1] ENST00000679016.1 ENST00000678348.1 [O15393-1] A0A7I2YQ98 C9JB05 C9JKZ3 ENST00000679181.1 ENST00000679054.1 [O15393-1] A0A7I2V509 ENST00000678959.1 ENST00000458356.6 [O15393-1] ENST00000676973.1 [O15393-1] ENST00000454499 Q96T73 A0A7I2V3D1 ENST00000398585.7 [O15393-2] A0A7I2V5N2 A0A7I2V474 A0A7I2V5F9 A0A7I2V650 ENST00000679263.1 ENST00000678171.1 ENST00000455813.1

TMPRSS2 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review